Triptorelin Market Upcoming Trends, Demand and Analysis Till 2026
Triptorelin is a peptide formulation for injection that was developed mainly for the treatment of advanced metastatic prostate cancer. Furthermore, other indications developed subsequently include the treatment of uterine fibroids (a benign tumor of muscle tissues in the uterus), endometriosis (proliferation of endometrial tissue, the mucous membrane that lines the uterine wall outside the reproductive tract) prior to surgery or when surgery is not deemed appropriate, as well as early onset puberty and female infertility (in vitro fertilization). Other modalities of triptorelin such as triptorelin acetate, triptorelin pamoate and triptorelin embonate are also used for prostate cancer treatment.
Market Dynamics
Triptorelin market is expected to witness lucrative growth opportunities during forecast period, owing to increasing incidence of prostate cancer and salivary gland cancer and increasing prevalence of central precocious puberty among the young patients below age eight and nine years, worldwide. For instance, according to National Organization for Rare Disorders (NORD), 2016 data findings, Central Precocious Puberty (CPP), accounted for 1 to 5 in 10,000 children with a female to male ratio of about 20:1, in U.S.
In March 2017, Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, in coordination with fourteen other European regulatory agencies approved a new indication of Decapeptyl (triptorelin).
According to these new indication, Decapeptyl (triptorelin) will be used as adjuvant treatment in combination with tamoxifen or aromatase inhibitor for endocrine-responsive early-stage breast cancer in women at high-risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy. This would enhance the revenue for growth for triptorelin market, during forecast period.
Furthermore, higher efficacy and tolerability of triptorelin in suppression of gonadotropin secretion in prostate cancer and precocious puberty is increasing adoption of triptorelin in the market.
